EcoDrugPlus

Calcium Voltage-Gated Channel Subunit Alpha1 A

Ensembl ID : ENSAMXG00000010767
Gene Symbol: CACNA1A
1 Cross references
198 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 B

Ensembl ID : ENSAMXG00000012714
Gene Symbol: CACNA1B
1 Cross references
215 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 D

Ensembl ID : ENSAMXG00000014965
Gene Symbol: CACNA1D
1 Cross references
210 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 E

Ensembl ID : ENSAMXG00000008956
Gene Symbol: CACNA1E
1 Cross references
208 Possible Orthologues:

Calcium Voltage-Gated Channel Subunit Alpha1 I

Ensembl ID : ENSAMXG00000019975
Gene Symbol: CACNA1I
1 Cross references
191 Possible Orthologues:

Cannabinoid Receptor 2

Ensembl ID : ENSAMXG00000041379
Gene Symbol: CNR2
1 Cross references
196 Possible Orthologues:

Carbonic Anhydrase 12

Ensembl ID : ENSAMXG00000038724
Gene Symbol: CA12
3 Cross references
215 Possible Orthologues:

Carbonic Anhydrase 14

Ensembl ID : ENSAMXG00000036060
Gene Symbol: CA14
3 Cross references
209 Possible Orthologues:

Carbonic Anhydrase 4-Like

Ensembl ID : ENSAMXG00000003989
Gene Symbol: LOC103022249
3 Cross references
198 Possible Orthologues:

Carbonic Anhydrase 4-Like

Ensembl ID : ENSAMXG00000043073
Gene Symbol: LOC103038820
3 Cross references
214 Possible Orthologues:

Carbonic Anhydrase 4-Like

Ensembl ID : ENSAMXG00000041730
Gene Symbol: LOC103043744
3 Cross references
201 Possible Orthologues:

Carbonic Anhydrase 5b, Mitochondrial

Ensembl ID : ENSAMXG00000036434
Gene Symbol: LOC103039663
3 Cross references
231 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).